Search Results

You are looking at 1 - 5 of 5 items for :

  • "treatment resistance" x
Clear All
Restricted access

Soojin Kim, Daksh Thaper, Samir Bidnur, Paul Toren, Shusuke Akamatsu, Jennifer L Bishop, Colin Colins, Sepideh Vahid and Amina Zoubeidi

deprivation therapy (ADT); however, treatment resistance is inevitable and tumors progress to castration-resistant PCa (CRPC) ( Davies et al. 2018 ). Persistent androgen receptor (AR) activity continues to be a driving force behind disease progression in

Free access

Irene I Lee, Nane C Kuznik, Jaice T Rottenberg, Myles Brown and Andrew C B Cato

supported by the following findings: (1) AR-V7 increases as patients progress from untreated hormone-sensitive prostate cancer (HSPC) to CRPC; (2) AR-V7 increases with emerging treatment resistance to abiraterone and enzalutamide; (3) AR-V7 is associated

Free access

Ke-Hung Tsui, Ying-Ling Chang, Tsui-Hsia Feng, Li-Chuan Chung, Tzu-Yi Lee, Phei-Lang Chang and Horng-Heng Juang

pleiotropic functions in cancer and might contribute to the proliferation, migration, invasion, metastasis, and treatment resistance of cancer cells as well as tumor-induced anorexia and weight loss in the late stages of cancer ( Mimeault & Batra 2010 ). In

Free access

Angela M Davis, Jiude Mao, Bushra Naz, Jessica A Kohl and Cheryl S Rosenfeld

receptor-β: implications for treatment resistance . International Journal of Oncology 27 1647 – 1659 . Yamamoto Y Moore R Hess HA Guo GL Gonzalez FJ Korach KS Maronpot RR Negishi M 2006 Estrogen receptor alpha mediates 17alpha

Free access

Tram B Doan, J Dinny Graham and Christine L Clarke

with ER+ breast tumors who develop endocrine treatment resistance ( Dixon 2014 ), patients with estrogen receptor-negative (ER−) breast cancers ( Hudis & Gianni 2011 ) and cancers that recur in all age groups ( EBCTCG 2005 ). Women in these subgroups